Chagas Disease Treatment Market - Global Industry Insights, Trends, Outlook, and Analysis, 2017-2025

American trypanosomiasis also known as Chagas disease is caused by the parasite Trypanosoma cruzi (T.cruzi), which is transmitted by the bite of triatomine bugs. The parasites hide during the day time and become active at night and feed on human blood. T. cruzi can also be transmitted by food contaminated with the parasite, blood transfusion, transmission from infected mother to newborn during gestational period, organ transplant, and laboratory accidents. Its symptoms are not severe and are often not diagnosed. The parasites hide mainly in the heart and digestive muscles during the chronic phase. After years of chronic infection, it become an important cause of human heart diseases (30 %), megacolon, and megaseophagus. Chagas disease is one of the neglected parasitic infection in the U.S., however it is targeted by the Center for Disease Control and Prevention (CDC) for community health action. People living in rural part of Latin America are primarily affected by Chagas disease. It is mostly found in the 21 endemic regions of Latin American countries.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/934

According to a report by WHO, 2017, over the past few decades, there has been increase in the detection of chagas disease in Canada, European region, and western pacific countries mainly due to increasing influx in the population of Latin America According to Food and Drug Administration (FDA), in 2017, around 300,000 people are estimated to be affected by chagas disease in the U.S. Furthermore, World Health Organization (WHO) stated that, around 6 million to 7 million people are expected to be affected by chagas disease in 2017. Vector control is the most useful method to prevent the spread of Chagas disease in Latin America. High incidence rate and easy transmission mode is expected to increase the demand for treatment of Chagas disease. Non availability of vaccines and biological treatment, is expected to create opportunity for the market players.

Chagas Disease Treatment Market Taxonomy

By Distribution Channel

Hospital Pharmacy,Retail Pharmacy,.

By Region

North America,Europe,Asia Pacific,Latin America,Middle East,Africa,.

Access Table of Content (TOC) Of the Report: https://www.coherentmarketinsights.com/ongoing-insight/toc/934

Unmet need of safe and effective drugs is expected to fuel the chagas disease treatment market growth

Countries like Venezuela have successful vector control program based on the improved rural housing and vector control. The use of nitro derivative compound drugs, which are associated with the host immune response, help to keep the disease in check and to avoid parasite proliferation. None of the drug are able to completely cure the disease. Drugs used for the treatment of Chagas disease, benznidazole, and nifurtimox, have serious side effects such as headache, skin rashes, photosensitivity, chest pain, dizziness, nausea, insomnia, jaundice and among others. Medication with less side effects is the unmet need of the chagas disease treatment market. Active partnership of state and local health department to educate them the way to take care of patients, is expected to propel the chagas disease treatment market growth in the near future.

Approval of first safe and effective therapy for Chagas disease by FDA, expected to propel the market players to develop novel drugs

In 2017, Food and Drug Administration (FDA) approved benznidazole for use in children between the age 2 and 12 years affected from chagas disease. It is the first approved safe and effective therapeutics in U.S. for the chagas disease treatment. FDA granted benznidazole priority review and orphan product designation, as it is a rare disease and there have been no approved drugs for its treatment in U.S. This approval is expected to propel the manufacturers to develop new drugs and biological products for the prevention and treatment of rare disease. Some of the major players operating in the global chagas disease treatment market include F. Hoffmann-La Roche Ltd., KaloBios Pharmaceuticals, Inc., Johnson & Johnson, Bayer AG., and ELEA SACIF Laboratory.

Browse The Report: https://www.coherentmarketinsights.com/ongoing-insight/chagas-disease-treatment-market-934

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: http://www.coherentnews.com

Contact US: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel : +1-206-701-6702 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com